Elagolix sodium
CAS No. : 832720-36-2
(Synonyms: NBI-56418 sodium)
| Size | Price | Stock |
|---|---|---|
| 5mg | $60 | In-stock |
| 10mg | $90 | In-stock |
| 25mg | $180 | In-stock |
| 50mg | $290 | In-stock |
| 100mg | $460 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-14369 |
| M.Wt: | 653.57 |
| Formula: | C32H29F5N3NaO5 |
| Purity: | >98 % |
| Solubility: | H2O : ≥ 50 mg/mL;DMSO : 50 mg/mL (ultrasonic) |
Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. [1][2][3][4][5].
IC50 & Target:IC50: 0.25 nM (GnRHR)[1]
Ki: 3.7 nM (GnRHR)[2]
In Vitro:Elagolix sodium is a human GnRH receptor (GnRHR) antagonist, with an IC50 of 0.25 nM in kinase assays[1].
Elagolix sodium also shows NFAT inhibitory effects, with an IC50 of 5.4 nM, and effectively blocks Ca2+ flux, with an IC50 of 0.86 nM[1].
Elagolix sodium is a human GnRH receptor (GnRHR) antagonist, with a Ki value of 3.7 nM[2].
In Vivo:
Main pharmacokinetic parameters after taking a single oral dose of Elagolix sodium to rats[2]
| Route | Dose (mg/kg) | AUC0→t (ng•h/mL) | AUC0→∞ (ng•h/mL) | t1/2 (h) | Tmax (h) | Cmax (ng/mL) |
| Oral | 15 | 5212 | 5301 | 6.56 | 1.50 | 1515 |